Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Maintenance of Bivalent Oral Poliovirus Vaccine Use
J Vaccines Vaccin; 2016 Oct 3; Duintjer Tebbens, et al
Countries with suboptimal routine immunization coverage should continue to conduct at least 1 annual supplemental immunization activity (SIA) with bivalent oral poliovirus vaccine (bOPV), preferably more, until global OPV13 cessation, a recent study concluded. The study examined the impact of different bOPV SIA strategies on population immunity to serotype 1 and 3 poliovirus transmission and circulating vaccine-derived poliovirus (cVDPV) risk before and after globally-coordinated cessation of serotype 1 and 3 oral poliovirus vaccine (OPV13 cessation). Researchers concluded:
- Maintaining high population immunity to serotype 1 and 3 transmission using bOPV SIAs significantly reduces:
- the risk of outbreaks due to imported serotype 1 and 3 viruses;
- the emergence of indigenous cVDPVs before or after OPV13 cessation; and
- the vulnerability to bOPV-related polio viruses in the event of nonsynchronous OPV13 cessation or inadvertent bOPV use after OPV13 cessation.
- Preventing cVDPV risks after OPV13 cessation requires investments in bOPV SIAs now through the time of OPV13 cessation.
Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccin. 2016;7:340. doi:10.4172/2157-7560.1000340.